Risk of Failure in Pipeline Discovery, Licensing and Development
First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2023.
0 other companies' latest entry also says "Other".
- FY2023Research and development delay and discontinuation risks re-disclosedAnnual report
「However, research and development may not produce the results originally planned, and plans may be delayed or discontinued.」
Although the wording differs from the previous pipeline discovery and out-licensing risks, the filing again explicitly identifies failure to achieve planned research and development results and the impact of delays or discontinuation on operating results and financial position as risks. - FY2020DroppedAnnual reportThe standalone risk disclosures previously covering drug-seed discovery, securing licensees or transferees, and development failures could not be found among the risk items in this filing.
- FY2019RestatedAnnual report
「If promising seeds cannot be discovered as expected, if no company can be found to which discovered seeds can be transferred or licensed, if the Group cannot secure the upfront payments or royalties it anticipates under contracts, or if development of candidate products is delayed or discontinued by the companies receiving the transfer or license, milestone payments and royalties cannot be recognized, potentially having a significant impact on the Group's future results and management plans.」
Restates the uncertainties surrounding drug-seed discovery, securing licensees or transferees, milestone payments and royalties, and continued development by licensees or transferees. - FY2017RestatedAnnual report
「However, if promising drug seeds cannot be identified as expected, if no company can be found to acquire or license them after they have been identified, if the milestone payments or royalties anticipated by the Group cannot be secured, or if development of a candidate product is delayed or discontinued by the company acquiring or licensing it, milestone payments and royalties may not be recognized, which could have a significant impact on the Group's future operating results and financial position.」
Restates the uncertainties surrounding drug-seed discovery, securing licensees or transferees, milestone payments and royalties, and development by licensees or transferees. - FY2016First statedAnnual report
「If promising seeds cannot be discovered as expected, if no company can be found to which discovered seeds can be transferred or licensed, if the Group cannot secure the upfront payments or royalties it anticipates under contracts, or if development of candidate products is delayed or discontinued by the companies receiving the transfer or license, milestone payments and royalties cannot be recognized, potentially having a significant impact on the Group's future results and management plans.」
The Company identifies multiple uncertainties relating to the discovery of seeds, securing out-licensees, upfront payments and royalties, and the continuation of development by licensees.